Corrigendum: Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial sepsis by inhibiting neutrophil extracellular traps.

Saved in:
Bibliographic Details
Title: Corrigendum: Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial sepsis by inhibiting neutrophil extracellular traps.
Authors: de Araujo CV; Department of Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, United States.; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States., Denorme F; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States., Stephens WZ; Department of Pathology, University of Utah, Salt Lake City, UT, United States., Li Q; High Throughput Genomics and Bioinformatic Analysis Shared Resource, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States., Cody MJ; Department of Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, United States.; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States., Crandell JL; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States., Petrey AC; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States.; Department of Pathology, University of Utah, Salt Lake City, UT, United States., Queisser KA; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States.; Department of Pathology, University of Utah, Salt Lake City, UT, United States., Rustad JL; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States., Fulcher JM; Department of Biochemistry, University of Utah, Salt Lake City, UT, United States., Evangelista JL; Department of Biochemistry, University of Utah, Salt Lake City, UT, United States., Kay MS; Department of Biochemistry, University of Utah, Salt Lake City, UT, United States., Schiffman JD; Department of Pediatrics/Hematology-Oncology, University of Utah, Salt Lake City, UT, United States.; Peel Therapeutics, Inc., Salt Lake City, UT, United States., Campbell RA; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States.; Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States., Yost CC; Department of Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, United States.; Molecular Medicine Program, University of Utah, Salt Lake City, UT, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Mar 29; Vol. 14, pp. 1171222. Date of Electronic Publication: 2023 Mar 29 (Print Publication: 2023).
Publication Type: Published Erratum
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1171222